Quest Laboratories Ltd.

As of March 31, 2026, Quest Laboratories Ltd. carries a market capitalization of 1.71B, placing it among publicly traded companies globally. Its enterprise value stands at 1.67B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of March 31, 2026, Quest Laboratories Ltd. has 16.39M shares outstanding.

As of March 31, 2026, Quest Laboratories Ltd. trades at a trailing price-to-earnings ratio of 24.93. The price-to-sales ratio is 2.96, and the price-to-book ratio stands at 1.77.

As of March 31, 2026, Quest Laboratories Ltd. trades at an EV/EBITDA multiple of 22.16 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 2.87 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 23.45 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 1.67B versus a market cap of 1.71B, with the gap driven by net debt and cash on the balance sheet.

As of March 31, 2026, Quest Laboratories Ltd. maintains a current ratio of 6.83, meaning it holds 6.8x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 8.14, indicating elevated leverage, while an interest coverage ratio of 10.10 demonstrates strong ability to service its debt obligations.

Over the twelve months ended March 31, 2026, Quest Laboratories Ltd. posted a return on equity (ROE) of 7.70, showing how much profit the company earns on every dollar of shareholder capital. Return on assets (ROA) stands at 5.89, measuring how efficiently the asset base is converted into earnings. The company generates approximately 7.79M in revenue per employee across its workforce of 74.50, a quick read on workforce productivity versus industry peers. Inventory turnover of 1.60 indicates how many times Quest Laboratories Ltd. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended March 31, 2026, Quest Laboratories Ltd. recorded an income tax benefit of -4.09M rather than an expense, typically from losses, carryforwards, or the release of a tax provision. Taxes are levied on pretax income of 64.78M, leaving 68.87M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 22, 2026, Quest Laboratories Ltd.'s stock has declined approximately 2.18% over the past 52 weeks. The 50-day moving average sits at 87.55, while the 200-day moving average is 102.87.

Over the twelve months ended March 31, 2026, Quest Laboratories Ltd. generated 580.25M in revenue and converted that into 68.87M in net income, yielding earnings per share of 4.19. EBITDA reached 75.22M, while operating income came in at 71.09M.

As of March 31, 2026, Quest Laboratories Ltd. holds 122.86M in cash and equivalents against 78.85M in total debt, resulting in a net debt position of 77.81M. Total book value stands at 968.22M, with working capital of 790.25M providing operational flexibility.

Over the twelve months ended March 31, 2026, Quest Laboratories Ltd. posted a gross margin of 17.33, reflecting its pricing power and cost economics. The operating margin of 12.25 and net profit margin of 11.87 provide insight into operational efficiency.

As of March 31, 2026, Quest Laboratories Ltd. has an Altman Z-Score of 8.79, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.